Exopharm Ltd (EX1) TRADING HALT SUSPENDED

20mins delayed

Movement

1 Year Return


Exopharm Ltd Chart

Share price
Last
Change
Volume
Turnover
Market Cap $26.36 million
Today's Movement
Prev. Close
Open
Day Range -
VWAP
Historical Stats
52w Range -
4w Avg Volume
4w Avg Turnover
(delayed)

EX1 Statistics

01 October

1,440 / 2,232

ASX Size Rank

1yr Return

vs Sector (1yr)

-41.93%

vs ASX 200 (1yr)

-11.62%

$26.36 million

Market Cap

Share Issue

83.68 million

All Ords (%)

N/A

Short Sold

0%

Current Fundamentals

01 October

N/A

PE Ratio

EPS ($)

-0.056

Earnings Yield

-17.84%

NTA ($)

0.04

N/A

Dividend Yield

DPS ($)

-

Gross Div. Yield

-

Gross DPS ($)

-

Company Overview

Exopharm Limited (EX1) is an Australian biopharmaceutical company that deals in developing regenerative medicine, primarily being the development and de-risking of exosome technologies, particularly the LEAP manufacturing process and development of the PlexarisTM and ExomereTM products.

Exopharm Ltd Logo

Corporate Details

Head Office: Melbourne
Managing Director: Ian Dixon
GICS Sub-Industry: Biotechnology
Date Listed: 18 Dec 2018
Registry: Automic
Similar Companies: CSL / MSB / CUV / OPT / AVH

Upcoming Calendar

Dividend History

Ex-Date Amount Franking Type Payable
No dividends paid in the last 5 years

See Upcoming Dividends for all ASX companies.

Announcements

Date Heading Pages File Size Time

Announcements provided by

Broker Consensus

The buy, hold and sell recommendations from Australian stockbroking firms are combined to form a "broker consensus". See the Consensus Data posts for more information.

EX1 is not covered by a major broker,
or data from most recent compilation was omitted due
to not meeting QA guidelines.

Directors & Management

About the Data


Name Title Since Bio
Mr David Rodney Parker Non-Executive Director Jun 2018
Dr Ian Edward Dixon Managing Director May 2013
Mr Jason Mark Watson Non-Executive Chairman, Non-Executive Director Aug 2018
Christopher Baldwin Chief Commercial Officer N/A
Gregory Lichtfuss Chief Operating Officer N/A
Sinead Teague Company Secretary N/A

Director Transactions

About the Data

EX1 directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
13/09/19 Jason Watson Issued 100,000 $0.370 $37,000 Placement.
19/08/19 David Parker Buy +20,000 $0.370 $7,400 Participation in share purchase plan.
19/08/19 Ian Dixon Buy +40,000 $0.370 $14,800 Participation in share purchase plan.
19/08/19 Jason Watson Buy +40,000 $0.370 $14,800 Participation in share purchase plan.

Shareholder Distribution

About the Data

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over Total Shareholders
No. of Shareholders 31 184 173 561 156 1,105

Top 20 Shareholders

About the Data

Name Shares Capital
Altnia Holdings Pty Ltd 27,975,294 29.30%
Mr Michael Francis Mcmahon & Mrs Susan Lesley Mcmahon 2,276,849 2.38%
Oldview Enterprises Pty Ltd 1,432,585 1.50%
Kohen Enterprises Pty Ltd 1,350,000 1.41%
Anthony John Locantro 1,330,000 1.39%
Phytose Corporation Pty Limited 1,176,471 1.23%
Carda Pty Ltd 1,170,000 1.23%
Mrs Anna Felicia Belton 1,023,334 1.07%
Zessham Pty Ltd 950,000 1.00%
Acns Capital Markets Pty Ltd 800,000 0.84%
Drp 2006 Super Pty Ltd 760,000 0.80%
Saintly Company Pty Ltd 636,000 0.67%
Kyriaco Barber Pty Ltd 635,000 0.67%
Mr John Gardner 600,271 0.63%
Gregor Lichtfuss 588,235 0.62%
Jeccs Pty Ltd 545,000 0.57%
Mr Wayne John Hogan & Mrs Angela Patrice Hogan 500,000 0.52%
Ringsford Pty Ltd 500,000 0.52%
Mr Andrew Stewart Coles & Ms Alexandra Constance Manook 475,000 0.50%
Aukera Capital Pty Ltd 460,000 0.48%
All other shareholders 52.67 %


The Top 20 Shareholders of EX1 hold 47.33% of shares on issue.

EX1 Share Price History

Date Close Change % Change Open High Low Volume Turnover

EX1 Historical Data

Download up to 20 years of share price history.


Year Closing Price (30 June) Last Trade
2020 $0.25 30 June
2019 $0.41 28 June

Offical data as published by ASX. See more Data Downloads.

Company Details

Principal Activity: Investment in biopharmaceutical drug development.

Incorporated: --

Level 17, 31 Queen St
Melbourne VIC 3000


All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.